Distribution of hepatitis B virus genotypes in Korea

Cho, Ji-Hyun; Yoon, Kui-Hyun; Lee, Key-Earn; Park, Do‐Sim; Lee, Young Jin; Moon, Hyung–Bae; Lee, Kyoung R.; Choi, Chang-Soo; Cho, Eunyoung; Kim, Haak-Cheoul

doi:10.3350/kjhep.2009.15.2.140

Cited by 45 publications

(44 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, when we compared the HBsAg seroclearance rate for the same age group of less than 39 years of age, the HBsAg seroclearance rate in our study was lower (0.48%) compared to 0.96% in the Taiwan study [4]. It may be explained by the difference in viral genotypes between Korea (exclusively genotype C) and Taiwan (genotype B and C) [13,14,15,16,17]. The genotype might also affect the serum HBsAg levels and HBsAg seroclearance rates [9,18,19].…”

Section: Discussioncontrasting

confidence: 38%

Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients

Kwak¹,

Cho²,

Jang³

et al. 2011

Digestion

View full text Add to dashboard Cite

Background and Aims: In chronic hepatitis B virus (HBV) infections, hepatitis B surface antigen (HBsAg) seroclearance reportedly occurs at a rate of 0.50–2.26%. Several factors were suggested to be associated with seroclearance including age and HBeAg negativity. However, there are few studies evaluating whether HBV DNA levels are an independent predictor of HBsAg seroclearance. The aim of this study was to evaluate the annual HBsAg seroclearance rate and its predictors including serum HBV DNA levels in HBeAg-negative chronic hepatitis B patients. Methods: We included 880 HBeAg-negative chronic hepatitis B patients who underwent an evaluation of baseline serum HBV DNA levels. We reviewed the electronic charts for baseline clinical, biochemical, and virological factors. Results: The median age was 50 years, and the follow-up duration was 31 months. The annual rate for the HBsAg seroclearance was 1.8%. In multivariable analysis, the probability of HBsAg seroclearance was positively associated with old age (p = 0.046), with a sustained inactive phase rather than the occurrence of HBeAg-negative hepatitis (p = 0.041), and with an initial HBV DNA level <2,000 IU/ml (p = 0.001). Conclusion: The annual rate for the HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients was 1.8%. Old age, sustained inactive phase, and low levels of HBV DNA were independent predictors of HBsAg seroclearance.

show abstract

Section: Discussioncontrasting

confidence: 38%

Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients

Kwak¹,

Cho²,

Jang³

et al. 2011

Digestion

View full text Add to dashboard Cite

show abstract

“…Patients with other causes of chronic liver injury, such as autoimmune hepatitis, alcoholic hepatitis, Wilson’s disease, and primary biliary cirrhosis, were excluded. Since almost all Korean patients with CHB are reported to be infected with genotype C virus, the enrolled patients were assumed to be genotype C HBV carriers 15–17…”

Section: Methodsmentioning

confidence: 99%

Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients

et al. 2017

View full text Add to dashboard Cite

Background/AimsWe aimed to clarify the association of hepatitis B surface antigen (HBsAg)/hepatitis B core antigen (HBcAg) with the disease status and treatment response in patients with chronic hepatitis B (CHB).MethodsWe investigated 171 biopsy-proven entecavir-treated CHB patients (109 hepatitis B e antigen [HBeAg]-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous. The histologic activity index (HAI) and fibrosis stage followed Ishak system.ResultsIn HBeAg-positive patients, older age, increased HAI score, advanced fibrosis, and reduced viral load were observed when HBcAg expression shifted from nucleus to cytoplasm in HBcAg-positive patients, and HBsAg expression from non-submembranous to submembranous in HBcAg-negative patients (all, p<0.05). In HBeAg-negative patients, only intracytoplasmic HBsAg expression patterns had clinical relevance with decreased ALT levels and viremia. In HBeAg-positive patients without favorable predictors of virologic response, negative HBcAg and membranous HB-sAg expression predicted greater virologic response (both, p<0.05). The probability of HBeAg seroclearance was higher in patients with increased HAI or lacking HBcAg expression (both, p<0.05). Higher serum HBsAg levels and hepatocyte HBcAg positivity were associated with reduced serum HBsAg during first and post-first year treatment, respectively (both, p<0.05).ConclusionsHepatocyte HBcAg/HBsAg expression is a good marker for disease status and predicting treatment response.

show abstract

“…However, the most prevalent HBV genotype in Korea is C2, which accounted for 98.1% (370/377) of the total HBV cases in a recent domestic study. 26 Thus, our conclusions may be regarded as being drawn from the C2 genotype. In a recent study, HBV genotypes did not significantly affect the correlation between the 2 qHBsAg assays, 17 but further research would elucidate the effect of HBV genotype differences on the correlations in the levels of HBsAg, HBcrAg, and HBV DNA.…”

Section: Discussionmentioning

confidence: 98%

Performance Evaluation of New Automated Hepatitis B Viral Markers in the Clinical Laboratory

et al. 2012

View full text Add to dashboard Cite

We evaluated quantitative hepatitis B surface antigen (qHBsAg) assays and a hepatitis B virus (HBV) core-related antigen (HBcrAg) assay. A total of 529 serum samples from patients with hepatitis B were tested. HBsAg levels were determined by using the Elecsys (Roche Diagnostics, Indianapolis, IN) and Architect (Abbott Laboratories, Abbott Park, IL) qHBsAg assays. HBcrAg was measured by using Lumipulse HBcrAg assay (Fujirebio, Tokyo, Japan). Serum aminotransferases and HBV DNA were respectively quantified by using the Hitachi 7600 analyzer (Hitachi High-Technologies, Tokyo, Japan) and the Cobas AmpliPrep/Cobas TaqMan test (Roche). Precision of the qHBsAg and HBcrAg assays was assessed, and linearity of the qHBsAg assays was verified. All assays showed good precision performance with coefficients of variation between 4.5% and 5.3% except for some levels. Both qHBsAg assays showed linearity from 0.1 to 12,000.0 IU/mL and correlated well (r = 0.9934). HBsAg levels correlated with HBV DNA (r = 0.3373) and with HBcrAg (r = 0.5164), and HBcrAg also correlated with HBV DNA (r = 0.5198; P < .0001). This observation could provide impetus for further research to elucidate the clinical usefulness of the qHBsAg and HBcrAg assays.

show abstract

Distribution of hepatitis B virus genotypes in Korea

Abstract: The prevailing HBV genotype in Korea is C2; the other genotypes occur only rarely. Future studies should include confirmation of the detection of genotypes other than C.

Cited by 45 publications

References 30 publications

Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients

Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients

Expression of Hepatocyte Hepatitis B Core Antigen and Hepatitis B Surface Antigen as a Marker in the Management of Chronic Hepatitis B Patients

Performance Evaluation of New Automated Hepatitis B Viral Markers in the Clinical Laboratory

Contact Info

Product

Resources

About